We examined the incidence of myositis and myocarditis across a cohort of patients receiving ICB for melanoma and renal cell carcinoma from end 2015 to end 2021,3 14–16 (n=135 who received combination programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blockade, n=102 who received single-agent anti-PD-1). Here, PDCD1 is linked to myositis disease.